Glycogen synthase kinase-3: A potential immunotherapeutic target in tumor microenvironment - 22/03/24
Abstract |
Glycogen synthase kinase-3(GSK-3) is a protein kinase that can phosphorylate over a hundred substrates and regulate cell differentiation, proliferation, and death. Researchers have acknowledged the pivotal role of abnormal activation of GSK-3 in the progression of various diseases over the past few decades. Recent studies have mostly concentrated on investigating the function of GSK-3 in the tumor microenvironment, specifically examining the interaction between TAM, NK cells, B cells, and T cells. Furthermore, GSK-3 exhibits a strong association with immunological checkpoints, such as programmed cell death protein 1. Novel GSK-3 inhibitors have potential in tumor immunotherapy, exerting beneficial effects on hematologic diseases and solid tumors. Nevertheless, there is a lack of reviews about the correlation between tumor-associated immune cells and GSK-3. This study intends to analyze the function and mechanism of GSK-3 comprehensively and systematically in the tumor microenvironment, with a special focus on its influence on various immune cells. The objective is to present novel perspectives for GSK-3 immunotherapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Multiple roles of GSK-3 in tumor microenvironment are summarized. |
• | GSK-3 inhibitors show therapeutic promise for refractory tumors. |
• | The current status of GSK-3 inhibitors in tumor immunology is summarized. |
• | The perspectives of GSK-3 inhibitors in tumor immunology are discussed. |
Abbreviations : GSK-3, PI3K, Wnt, AKT, MTORC1, TIGIT, EMT, TME, CAFs, TAM, PD-1, NK cells, PDAC, ECM, TCR, NFAT, NF-κB, LAG-3, HCC, MAPK, OXPHOS, CRAD, AIM, VAT, PBMC, OS, CTL, MHC, ULBP, DC, ADCC, ROS, BCR, MLL, ILQ, Tr1, Th17, LPS, AFGF1, AIDS, SLE, T-ALL, TIL, HIV, MDSC, FGF1, HSC, AGE, IPF, MM, MTD
Keywords : GSK-3, Tumor microenvironment, Immunotherapy, NK cells, T cells
Plan
Vol 173
Article 116377- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?